⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INCY News
Incyte Genomics Inc
Non-Small Cell Lung Cancer Market Poised for Robust Expansion at a 6.6% CAGR Through 2036, Driven by Emerging Targeted and Immunotherapy Innovations | DelveInsight
prnewswire.com
PFE
ABBV
RMD
GSK
AZN
BNTX
INCY
IOVA
RGEN
MRK
LLY
IBIO
GILD
AMGN
JNJ
NVS
RIGL
BIIB
Warm Autoimmune Hemolytic Anemia Market to Observe Stunning Growth at a 14.4% CAGR During the Forecast Period (2026-2036) Due to the Emergence of Novel Drug Classes Such as FcRn Inhibitors, BTK Inhibitors, BAFF-R, and Others | DelveInsight
prnewswire.com
JNJ
SNY
NVS
INCY
Incyte annonce un avis favorable du CHMP concernant la crème Opzelura® (ruxolitinib) pour le traitement des adultes atteints de dermatite atopique modérée
businesswire.com
INCY
Riassunto: Incyte annuncia l'opinione positiva del CHMP per Opzelura® (ruxolitinib) crema per il trattamento della dermatite atopica moderata in pazienti adulti
businesswire.com
INCY
Incyte gibt positive Stellungnahme des CHMP zu Opzelura ® (Ruxolitinib)-Creme zur Behandlung von Erwachsenen mit mittelschwerer atopischer Dermatitis bekannt
businesswire.com
INCY
Resumen: Incyte anuncia un dictamen favorable del CHMP sobre la crema Opzelura® (ruxolitinib) para tratar a los pacientes adultos con dermatitis atópica moderada
businesswire.com
INCY
Samenvatting: Incyte kondigt positief CHMP-advies aan voor Opzelura® (ruxolitinib)-crème voor de behandeling van volwassenen met matige atopische dermatitis
businesswire.com
INCY
Form 8-K
sec.gov
INCY
Riassunto: Incyte Japan annuncia l'approvazione di Minjuvi® (tafasitamab) in combinazione con lenalidomide per il trattamento di pazienti adulti con linfoma diffuso a grandi cellule B (DLBCL) recidivante o refrattario
businesswire.com
INCY
Resumen: Incyte Japón anuncia la autorización de Minjuvi® (tafasitamab) en combinación con lenalidomida para el tratamiento de adultos con linfoma difuso de células B grandes (DLBCL) recidivante o refractario
businesswire.com
INCY